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of the hand. However, these described complications may 
ultimately result in upper extremity dysfunction in patients.
Zwaan and colleagues performed an extensive systematic 
review and meta-analysis on all access site complications and 
subsequent upper extremity dysfunction following TR-PCI 
and cardiac catheterisation [9]. Upper extremity dysfunc-
tion was defined as loss of strength, sensory loss, coordina-
tion and/or loss of active range of motion, ascertained by 
patient history and/or through physical examination. Other 
reported complications of TR-PCI included upper extremity 
ischaemia, pain, radial artery spasm, radial artery occlusion, 
access site bleeding, access site haematoma, perforation, 
dissection, swelling, compartment syndrome, pseudo-
aneurysm, arteriovenous fistula, and infection/inflamma-
tion. A total of 176 studies were found eligible, including 
14 articles on the incidence of upper extremity dysfunction. 
The authors report a pooled incidence of upper extremity 
dysfunction following TR-PCI and cardiac catheterisation 
of 0.32 % (0.10–1.01). There are some discrepancies among 
the included studies on how upper extremity dysfunction 
was assessed, which varies from investigating the handgrip 
strength to evaluating functional loss by history of follow-
up. In particular in the former situation, this could result 
in underestimation of upper extremity dysfunction. Thus, it 
is questionable and a limitation of the study to lump these 
studies together. However, restricting the included studies to 
a more uniform assessment of upper extremity dysfunction 
would severely limit the eligible studies. Other frequently 
reported complications following TR-PCI and catheterisa-
tions included pain with a mean pooled incidence of 7.65 % 
(4.51–12.67), early radial artery occlusion with a pooled 
incidence of 3.45 (2.59–4.58) and late radial artery occlu-
sion with a pooled incidence of 3.34 % (2.57–4.32).
Recently Van Leeuwen et al. prospectively investigated 
upper limb function in 338 patients undergoing coronary 
Following the introduction of transradial percutaneous cor-
onary intervention (TR-PCI), a superficial and readily com-
pressible access site, there have been several randomised 
controlled trials where TR-PCI was compared with trans-
femoral PCI. Currently, the radial artery is the preferred 
access route for catheterisation and PCI, mainly due to the 
lower number of access site related complications [1]. In 
particular in ST-segment elevation myocardial infarction 
patients, TR-PCI was associated with lower rates of mortal-
ity, and major and access site bleeding compared with the 
transfemoral approach [2−5]. Bleeding is among the most 
common in-hospital complications of PCI and is indepen-
dently associated with increased mortality [6, 7]. Moreover, 
TR-PCI allows fast mobilisation of the patient and aids in 
reducing the in-hospital stay of STEMI patients [8].
Despite these clinical advantages, TR-PCI is technically 
more challenging due to the complex anatomical variabil-
ity of nerves and blood vessels in the upper extremity. The 
radial artery is more susceptible to vasospasm, in particu-
lar in elderly, female and diabetic patients. This is often 
ascribed to the smaller calibre of the artery. Complications 
following TR-PCI include radial artery spasm, radial artery 
occlusion, access site bleeding, perforation, dissection, 
compartment syndrome, pseudo-aneurysm, arteriovenous 
fistula, infection and inflammation, swelling and pain. Of 
these complications, radial artery occlusion is the most com-
mon with a pooled incidence rate of up to 5 %. This is often 
asymptomatic or subclinical due to the collateral circulation 
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catheterisation, including 85 % with a radial and 15 % a 
femoral approach [10]. Patients had to complete two ques-
tionnaires, including a self-reported shortened version of the 
Disabilities of Arm, Shoulder, and Hand and Cold Intoler-
ance Symptom Severity questionnaire, prior to catheterisa-
tion and at 30-days follow-up. In their study, upper limb 
function assessed by both questionnaires did not change 
significantly over time (prior to catheterisation to 30 days) 
when the operator choose a transradial approach. More-
over, the number of procedure-related extremity symptoms 
that persisted during 30-day follow-up was not different 
between the two access groups (transradial access 10.5 %, 
transfemoral 11.5 %; p = 0.82). Although these results sug-
gest that upper limb function is not jeopardised in a transra-
dial approach, it should be noted that the two patient groups 
differed significantly in sample size.
Also, it is unclear whether a questionnaire or a hand-grip 
strength would be a better measurement of upper extremity 
dysfunction. More appropriate insights into upper extremity 
dysfunction could be obtained by using a questionnaire in 
combination with an objective measurement of motor skills 
and sensory function measured prior to the procedure and 
at follow-up.
In summary, the findings of the aforementioned studies 
indicate the safety of TR-PCI with respect to the incidence 
of upper extremity dysfunction. Nevertheless, definite con-
clusions cannot be made based on the current literature and 
larger sized trials of a prospective design using uniform 
methods for determining upper extremity dysfunction are 
needed. Particularly in patients with an abnormal dual arte-
rial supply, the incidence of upper extremity dysfunction 
needs to be considered as these patients have a higher risk 
of complications.
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